These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 19075984)

  • 1. Novel promising therapeutic agents in multiple sclerosis.
    Mirshafiey A
    Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):218-4. PubMed ID: 19075984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic approach to multiple sclerosis by novel oral drug.
    Jadidi-Niaragh F; Mirshafiey A
    Recent Pat Inflamm Allergy Drug Discov; 2011 Jan; 5(1):66-80. PubMed ID: 21184668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease modifying drugs in multiple sclerosis: mechanisms of action and new drugs in the horizon.
    Marta M; Giovannoni G
    CNS Neurol Disord Drug Targets; 2012 Aug; 11(5):610-23. PubMed ID: 22583439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Towards immunotherapeutic drugs and vaccines against multiple sclerosis.
    Katsara M; Matsoukas J; Deraos G; Apostolopoulos V
    Acta Biochim Biophys Sin (Shanghai); 2008 Jul; 40(7):636-42. PubMed ID: 18604455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quinpramine: revival of old anti-inflammatory principles in multiple sclerosis?
    Haghikia A; Gold R
    Exp Neurol; 2009 Jun; 217(2):240-1. PubMed ID: 19361499
    [No Abstract]   [Full Text] [Related]  

  • 6. Emerging therapies in multiple sclerosis.
    Farrell R; Heaney D; Giovannoni G
    Expert Opin Emerg Drugs; 2005 Nov; 10(4):797-816. PubMed ID: 16262563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigational immunosuppressants in early-stage clinical trials for the treatment of multiple sclerosis.
    Gajofatto A; Turatti M
    Expert Opin Investig Drugs; 2018 Mar; 27(3):273-286. PubMed ID: 29455558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Experimental methods in the treatment of multiple sclerosis--new possibilities and hopes].
    Szczepanik M; Tutaj M; Filipczak-Bryniarska I; Bryniarski K
    Przegl Lek; 2005; 62(2):115-8. PubMed ID: 16095157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Flavonoids, the compounds with anti-inflammatory and immunomodulatory properties, as promising tools in multiple sclerosis (MS) therapy: A systematic review of preclinical evidence.
    Bayat P; Farshchi M; Yousefian M; Mahmoudi M; Yazdian-Robati R
    Int Immunopharmacol; 2021 Jun; 95():107562. PubMed ID: 33770729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in the pharmacological control of experimental allergic encephalomyelitis (EAE) and the implications for multiple sclerosis treatment.
    Bolton C
    Mult Scler; 1995 Nov; 1(3):143-9. PubMed ID: 9345444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotective natural products against experimental autoimmune encephalomyelitis: A review.
    Mohtashami L; Shakeri A; Javadi B
    Neurochem Int; 2019 Oct; 129():104516. PubMed ID: 31376428
    [No Abstract]   [Full Text] [Related]  

  • 12. Are current disease-modifying therapeutics in multiple sclerosis justified on the basis of studies in experimental autoimmune encephalomyelitis?
    Farooqi N; Gran B; Constantinescu CS
    J Neurochem; 2010 Nov; 115(4):829-44. PubMed ID: 20807309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SIRT1 and NAD+ precursors: Therapeutic targets in multiple sclerosis a review.
    Nimmagadda VK; Makar TK; Chandrasekaran K; Sagi AR; Ray J; Russell JW; Bever CT
    J Neuroimmunol; 2017 Mar; 304():29-34. PubMed ID: 27474445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Update of the treatment of multiple sclerosis].
    Miyamoto K
    Nihon Rinsho; 2013 May; 71(5):817-21. PubMed ID: 23777088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The prospects of minocycline in multiple sclerosis.
    Chen X; Ma X; Jiang Y; Pi R; Liu Y; Ma L
    J Neuroimmunol; 2011 Jun; 235(1-2):1-8. PubMed ID: 21565409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oral drugs in multiple sclerosis therapy: an overview and a critical appraisal.
    D'Amico E; Leone C; Caserta C; Patti F
    Expert Rev Neurother; 2015; 15(7):803-24. PubMed ID: 26098146
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple sclerosis: a review of existing therapy and future prospects.
    Khan OA
    J Pak Med Assoc; 1996 Jan; 46(1):20-4. PubMed ID: 8830165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Traditional concepts and future avenues of glucocorticoid action in experimental autoimmune encephalomyelitis and multiple sclerosis therapy.
    Lühder F; Reichardt HM
    Crit Rev Immunol; 2009; 29(3):255-73. PubMed ID: 19538138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peroxisome proliferator-activated receptor agonists as potential therapeutic agents in multiple sclerosis.
    Niino M
    Mini Rev Med Chem; 2007 Nov; 7(11):1129-35. PubMed ID: 18045216
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Investigational drug therapies of treatment of multiple sclerosis.
    Panitch HS
    Mult Scler; 1996 Sep; 2(2):66-77. PubMed ID: 9345383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.